Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 2

Heart rate in heart failure with mid-range ejection fraction

Pages
75–75
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, recent datadesignate that HFmrEF might be more similar to HFrEF (3)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart failure is a disease that has high mortality and morbidityrates.
📊
Key Findings & Data:However, as a syndrome, different phenotypes have beenintroduced by the European Society of Cardiology (ESC) 2016guidelines (1).
💡
Conclusion & Impact:However, recent datadesignate that HFmrEF might be more similar to HFrEF (3)
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Heart failure is a disease that has high mortality and morbidityrates. However, as a syndrome, different phenotypes have beenintroduced by the European Society of Cardiology (ESC) 2016guidelines (1). Heart failure with reduced ejection fraction (HFrEF)is the major phenotype in which evidence-based medicine withACE inhibitors or angiotensin receptor blockers (or ARNI in placeof these agents), beta blockers, mineralocorticoid receptorantagonists, and ivabradine play an important role (1). The ESC2016 guidelines introduced a novel phenotype, named heartfailure with mid-range ejection fraction (HFmrEF), in addition toanother major phenotype–heart failure with preserved ejectionfraction (HFpEF) (1). Among the two major phenotypes, HFmrEFremains in the “grey” or “transition” zone of diagnosis, withboth-sided transitions identifid in the literature (2). This littlebrother (or sister) was initially introduced to behave like HFpEF;hence, the diagnosis simulated HFpEF. However, recent datadesignate that HFmrEF might be more similar to HFrEF (3)

🔖

Cite This Article

YILMAZ, M. B. (2019). Heart rate in heart failure with mid-range ejection fraction. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 2, 75–75. https://ajindex.com/articles/365756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members;Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
  2. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-85
  3. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J, et al. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol 2017; 240: 265-70
  4. Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85: 1046-55
  5. Chow SL, Page RL 2nd, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther 2018; 16: 515-26
  6. Xin Y, Chen X, Zhao Y, Hu W. The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction. Anatol J Cardiol 2019; 21: 68-74
  7. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al.; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39: 26-35.